 In addition to its antihistamine properties, tripelennamine also acts as a weak serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).Because of its SRI properties, tripelennamine was used as the basis for the development of the selective serotonin reuptake inhibitor (SSRI) fluoxetine (Prozac).Tripelennamine was first synthesized in 1946 by Carl Djerassi, working in the laboratory of Charles Huttrer at CIBA, shortly after Djerassi got his B.S.